ClinicalTrials.gg
Status unknownNCT03312608CReMeUpdated Oct 18, 2017

Cerebral Reorganization in Cervical Myelopathy Measured by Navigated Transcranial Magnetic Stimulation

An observational study in Degenerative Myelopathy, sponsored by Charite University, Berlin, Germany. Status unknown at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-18.

Sponsored by Charite University, Berlin, Germany · Observational

The sponsor has not verified this record recently (last verified Oct 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
160
Ages
18 Years and older
Sex
All
01

Study summary

In degenerative cervical myelopathy (DCM) the dynamics of disease progression and the outcome after surgical decompression vary inter individually and do not necessarily correlate with radiological findings. By better characterization of the underlying pathophysiology this study aims to improve diagnostic power in DCM using Navigated transcranial magnetic stimulation (nTMS).

Read the detailed description

120 patients with DCM due to cervical spinal canal stenosis will be examined preoperatively and postoperatively with nTMS. On the basis of the initial Japanese Orthopedic Association (JOA) Score two patient groups will be established (JOA≤12/>12). The resting motor threshold, recruitment curve, cortical silent period and motor area will be determined. Accordingly, 40 healthy subjects will be examined.

To the investigators knowledge, this study is the first to analyze changes of corticospinal excitability and reorganization in patients with cervical spondylotic myelopathy with navigated TMS. In the present study, there was a significant difference in parameters of excitability and motor area activation between the severely symptomatic and clinically stable patient group. The investigators analysis showed that chronic CSM induces a recruitment of the non-primary motor area and corticospinal disinhibition, so that axonal damage can be compensated through recruitment of new cortical and supplementary motor connections, to a certain degree. Upon exhaustion of these mechanisms further axonal damage translates directly into new neurological deficits. These results lay the ground for a novel concept in CSM, the "corticospinal reserve capacity".

This study lays the foundation for future research to examine the pathomechanisms in CSM. Functional reorganization occurs on a spinal as well as on a cortical level. The concept of the corticospinal reseve capacity describes a compensatory, increased recruitment of non primary motor areas and corticospinal disinhibition in order to preserve motor function. By detecting the degree of reorganization, a stratification for an unfavourable as well as stable clinical course could be made. This innovative approach to describe the pathomechanisms in CSM might revise current concepts of clinical diagnostics and might have an impact on future treatment strategies.

02

Conditions studied

  • Degenerative Myelopathy

Browse trials for

Keywords

  • cerebral reorganization, TMS
03

In context

Spinal Cord Diseases

170 studies on the registry are indexed under Spinal Cord Diseases; 56 are open to participants now.

This study's planned enrollment of 160 is above the median of 100 across 45 observational studies indexed under Spinal Cord Diseases.

Browse Spinal Cord Diseases studies →

Lead sponsor

Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 129 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

  • patients with symptomatic/asymptomatic cervical spondylotic myelopathy scheduled for surgery or conservative Treatment
  • healthy subjects without any neurological disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with symptomatic/asymptomatic cervical spondylotic myelopathy scheduled for surgery (anterior and/ or posterior decompression) or conservative treatment. The radiological inclusion criteria are cervical spinal stenosis (C3-C7) associated with or without intramedullary high signal intensity lesion on T2-weighted MRI due to disc protrusion or spondylosis.
  • healthy subjects without any neurological disease

Exclusion criteria

Exclusion Criteria:

  • Exclusion criteria are other pathologies in the vicinity of the corticospinal tract above the lesion site (i.e. tumor, infarction), neuroinflammatory disease, high grade paresis of the upper extremity (BMRC\<3), the existence of a cardiac pacemaker, deep brain stimulation electrodes or pregnancy.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
160 participants (estimated)
Patient registry
No

Groups and cohorts

  • mild myelopathy (JOA>12)

    40 patients (JOA\>12) suffering from symptomatic or asymptomatic degenerative cervical myelopathy scheduled for surgery or conservative treatment. The radiological inclusion criteria are cervical spinal stenosis associated with or without intramedullary high signal intensity lesion on T2-weighted MRI. Exclusion criteria are other pathologies in the vicinity of the corticospinal tract above the lesion site (i.e. tumor, infarction), neuroinflammatory disease, high grade paresis of the upper extremity (BMRC\<3), the existence of a cardiac pacemaker, deep brain stimulation electrodes or pregnancy. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.

    Diagnostic Test: Navigated transcranial magnetic stimulation

  • moderate myelopathy

    40 patients (JOA≤12) suffering from symptomatic degenerative cervical myelopathy scheduled for surgery (anterior and/ or posterior decompression) or conservative treatment. The radiological inclusion criteria are cervical spinal stenosis associated with or without intramedullary high signal intensity lesion on T2-weighted MRI. Exclusion criteria are other pathologies in the vicinity of the corticospinal tract above the lesion site (i.e. tumor, infarction), neuroinflammatory disease, high grade paresis of the upper extremity (BMRC\<3), the existence of a cardiac pacemaker, deep brain stimulation electrodes or pregnancy. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.

    Diagnostic Test: Navigated transcranial magnetic stimulation

  • healthy control

    As a control group, 40 subjects will be included into the study. Exclusion criteria and examination protocol are identical with the patient group. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.

    Diagnostic Test: Navigated transcranial magnetic stimulation

Interventions

  • Diagnostic testNavigated transcranial magnetic stimulation
06

What researchers measure

Primary outcomes

  1. Corticospinal reserve capacity

    Comparison of corticospinal reserve capacity (defined by recruitment curve, cortical silent period, motor area) compared to healthy control group

    Time frame: preoperative

  2. Change in corticospinal reserve capacity

    Postoperative change in corticospinal reserve capacity compared to clinical symptoms

    Time frame: 9 months, 24 months postoperatively

07

Study locations

1 of 1 sites recruiting
  • Department of neurosurgery Charité
    Berlin, 10117, Germany
    Recruiting
    • Anna Zdunczyk, M.D. · Contactanna.zdunczyk@charite.de · 030/450660193
    • Peter Vajkoczy, M.D. · Principal investigator
    • Thomas Picht, M.D. · Principal investigator
    • Sandro Krieg, M.D. · Sub investigator
    • Carolin Weiss-Lucas, M.D. · Sub investigator
    • Kathleen Seidel, M.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — The study results, study protocol and study report will be shared with other Researchers during international congresses and peer reviewed publications

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: during the time of the study

Access criteria: only as a congress presentation or publication presenting the results of the study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2017 (actual). Primary completion is estimated for Jan 2021, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2017
First posted
Oct 18, 2017
StartActual
Jan 1, 2017
Primary completionEst.
Jan 1, 2021
CompletionEst.
Feb 1, 2023
Last update
Oct 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03312608
Collaborators
German Spine Society (Deutsche Wirbelsäulenstiftung), Insel Gruppe AG, University Hospital Bern, University Hospital of Cologne, University Hospital Munich
Responsible party
Anna Zdunczyk (principal investigator, physician, Charite University, Berlin, Germany) — Principal investigator
First posted
Oct 18, 2017
Start date
Jan 1, 2017
Primary completion
Jan 1, 2021 (estimated)
Completion
Feb 1, 2023 (estimated)
Last update
Oct 18, 2017

Study contacts

Anna Zdunczyk, M.D.
Contact
anna.zdunczyk@charite.de
004930450660193
Anna Zdunczyk, M.D.
principal investigator · Charite University, Berlin, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion